vs
Medpace Holdings, Inc.（MEDP）与3M（MMM）财务数据对比。点击上方公司名可切换其他公司
3M的季度营收约是Medpace Holdings, Inc.的8.5倍（$6.0B vs $708.5M）。Medpace Holdings, Inc.净利率更高（19.1% vs 10.8%，领先8.2%）。Medpace Holdings, Inc.同比增速更快（32.0% vs 1.3%）。3M自由现金流更多（$2.0B vs $188.1M）。过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs -1.8%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
3M是美国知名跨国综合企业，业务覆盖工业、劳动者安全防护、消费品等多个领域，总部位于圣保罗郊区的枫木市。公司现有超6万款产品，涵盖胶粘剂、研磨材料、防火防护产品、个人防护装备、窗膜、车漆保护膜、电子连接绝缘材料、汽车养护产品、光学膜等品类。
MEDP vs MMM — 直观对比
营收规模更大
MMM
是对方的8.5倍
$708.5M
营收增速更快
MEDP
高出30.7%
1.3%
净利率更高
MEDP
高出8.2%
10.8%
自由现金流更多
MMM
多$1.8B
$188.1M
两年增速更快
MEDP
近两年复合增速
-1.8%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $6.0B |
| 净利润 | $135.1M | $653.0M |
| 毛利率 | — | 40.7% |
| 营业利润率 | 21.6% | 23.2% |
| 净利率 | 19.1% | 10.8% |
| 营收同比 | 32.0% | 1.3% |
| 净利润同比 | 15.5% | -41.5% |
| 每股收益（稀释后） | $4.65 | $1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPMMM
| Q1 26 | — | $6.0B | ||
| Q4 25 | $708.5M | $6.1B | ||
| Q3 25 | $659.9M | $6.5B | ||
| Q2 25 | $603.3M | $6.3B | ||
| Q1 25 | $558.6M | $6.0B | ||
| Q4 24 | $536.6M | $6.0B | ||
| Q3 24 | $533.3M | $6.3B | ||
| Q2 24 | $528.1M | $6.3B |
净利润MEDPMMM
| Q1 26 | — | $653.0M | ||
| Q4 25 | $135.1M | $577.0M | ||
| Q3 25 | $111.1M | $834.0M | ||
| Q2 25 | $90.3M | $723.0M | ||
| Q1 25 | $114.6M | $1.1B | ||
| Q4 24 | $117.0M | $728.0M | ||
| Q3 24 | $96.4M | $1.4B | ||
| Q2 24 | $88.4M | $1.1B |
毛利率MEDPMMM
| Q1 26 | — | 40.7% | ||
| Q4 25 | — | 33.6% | ||
| Q3 25 | — | 41.8% | ||
| Q2 25 | — | 42.5% | ||
| Q1 25 | — | 41.6% | ||
| Q4 24 | — | 51.7% | ||
| Q3 24 | — | 42.1% | ||
| Q2 24 | — | 42.9% |
营业利润率MEDPMMM
| Q1 26 | — | 23.2% | ||
| Q4 25 | 21.6% | 13.0% | ||
| Q3 25 | 21.5% | 22.2% | ||
| Q2 25 | 20.9% | 18.0% | ||
| Q1 25 | 20.3% | 20.9% | ||
| Q4 24 | 23.4% | 12.2% | ||
| Q3 24 | 21.1% | 20.9% | ||
| Q2 24 | 19.9% | 20.3% |
净利率MEDPMMM
| Q1 26 | — | 10.8% | ||
| Q4 25 | 19.1% | 9.4% | ||
| Q3 25 | 16.8% | 12.8% | ||
| Q2 25 | 15.0% | 11.4% | ||
| Q1 25 | 20.5% | 18.7% | ||
| Q4 24 | 21.8% | 12.1% | ||
| Q3 24 | 18.1% | 21.8% | ||
| Q2 24 | 16.7% | 18.3% |
每股收益（稀释后）MEDPMMM
| Q1 26 | — | $1.23 | ||
| Q4 25 | $4.65 | $1.07 | ||
| Q3 25 | $3.86 | $1.55 | ||
| Q2 25 | $3.10 | $1.34 | ||
| Q1 25 | $3.67 | $2.04 | ||
| Q4 24 | $3.67 | $1.33 | ||
| Q3 24 | $3.01 | $2.48 | ||
| Q2 24 | $2.75 | $2.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $3.7B |
| 总债务越低越好 | — | $10.9B |
| 股东权益账面价值 | $459.1M | $3.3B |
| 总资产 | $2.0B | $35.4B |
| 负债/权益比越低杠杆越低 | — | 3.29× |
8季度趋势，按日历期对齐
现金及短期投资MEDPMMM
| Q1 26 | — | $3.7B | ||
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | — | ||
| Q2 25 | $46.3M | — | ||
| Q1 25 | $441.4M | — | ||
| Q4 24 | $669.4M | — | ||
| Q3 24 | $656.9M | — | ||
| Q2 24 | $510.9M | — |
总债务MEDPMMM
| Q1 26 | — | $10.9B | ||
| Q4 25 | — | $12.6B | ||
| Q3 25 | — | $12.6B | ||
| Q2 25 | — | $13.1B | ||
| Q1 25 | — | $13.5B | ||
| Q4 24 | — | $13.0B | ||
| Q3 24 | — | $13.2B | ||
| Q2 24 | — | $13.1B |
股东权益MEDPMMM
| Q1 26 | — | $3.3B | ||
| Q4 25 | $459.1M | $4.7B | ||
| Q3 25 | $293.6M | $4.6B | ||
| Q2 25 | $172.4M | $4.3B | ||
| Q1 25 | $593.6M | $4.5B | ||
| Q4 24 | $825.5M | $3.8B | ||
| Q3 24 | $881.4M | $4.6B | ||
| Q2 24 | $763.6M | $3.9B |
总资产MEDPMMM
| Q1 26 | — | $35.4B | ||
| Q4 25 | $2.0B | $37.7B | ||
| Q3 25 | $1.8B | $37.6B | ||
| Q2 25 | $1.6B | $38.0B | ||
| Q1 25 | $1.9B | $40.0B | ||
| Q4 24 | $2.1B | $39.9B | ||
| Q3 24 | $2.1B | $40.9B | ||
| Q2 24 | $1.9B | $43.4B |
负债/权益比MEDPMMM
| Q1 26 | — | 3.29× | ||
| Q4 25 | — | 2.68× | ||
| Q3 25 | — | 2.72× | ||
| Q2 25 | — | 3.06× | ||
| Q1 25 | — | 3.02× | ||
| Q4 24 | — | 3.40× | ||
| Q3 24 | — | 2.84× | ||
| Q2 24 | — | 3.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | — |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $2.0B |
| 自由现金流率自由现金流/营收 | 26.6% | 33.6% |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | $3.7B |
8季度趋势，按日历期对齐
经营现金流MEDPMMM
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $1.6B | ||
| Q3 25 | $246.2M | $1.8B | ||
| Q2 25 | $148.5M | $-954.0M | ||
| Q1 25 | $125.8M | $-79.0M | ||
| Q4 24 | $190.7M | $1.8B | ||
| Q3 24 | $149.1M | $-1.8B | ||
| Q2 24 | $116.4M | $1.0B |
自由现金流MEDPMMM
| Q1 26 | — | $2.0B | ||
| Q4 25 | $188.1M | $1.3B | ||
| Q3 25 | $235.5M | $1.5B | ||
| Q2 25 | $142.4M | $-1.2B | ||
| Q1 25 | $115.8M | $-315.0M | ||
| Q4 24 | $183.0M | $1.5B | ||
| Q3 24 | $138.5M | $-2.0B | ||
| Q2 24 | $103.5M | $752.0M |
自由现金流率MEDPMMM
| Q1 26 | — | 33.6% | ||
| Q4 25 | 26.6% | 21.8% | ||
| Q3 25 | 35.7% | 23.6% | ||
| Q2 25 | 23.6% | -18.3% | ||
| Q1 25 | 20.7% | -5.3% | ||
| Q4 24 | 34.1% | 25.4% | ||
| Q3 24 | 26.0% | -32.3% | ||
| Q2 24 | 19.6% | 12.0% |
资本支出强度MEDPMMM
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 4.0% | ||
| Q3 25 | 1.6% | 3.3% | ||
| Q2 25 | 1.0% | 3.3% | ||
| Q1 25 | 1.8% | 4.0% | ||
| Q4 24 | 1.4% | 4.8% | ||
| Q3 24 | 2.0% | 3.9% | ||
| Q2 24 | 2.4% | 4.3% |
现金转化率MEDPMMM
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 2.74× | ||
| Q3 25 | 2.22× | 2.11× | ||
| Q2 25 | 1.65× | -1.32× | ||
| Q1 25 | 1.10× | -0.07× | ||
| Q4 24 | 1.63× | 2.50× | ||
| Q3 24 | 1.55× | -1.30× | ||
| Q2 24 | 1.32× | 0.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
MMM
| Safety and Industrial business segment | $2.9B | 49% |
| Transportation and Electronics business segment | $1.8B | 31% |
| Consumer business segment | $1.1B | 19% |
| Corporate | $121.0M | 2% |
